Food and Drug Administration
February 18, 2005
Slides
Interpretation of Observed Differences in the Frequency of Events When the Number of Events is Small, Dr. Milton Packer, MD, FDA (HTM) (PPT)
Clinical Trial Design and Patient Safety: Future Directions for COX-2 Selective NSAIDs, Dr. Robert Temple, MD, FDA (HTM) (PPT)
Issues in Projecting Increased Risk of Cardiovascular Events to the Exposed Population, Dr. Robert O'Neill, PhD, FDA (HTM) (PPT)
Options for Action, Dr. Anne Trontell, MD, FDA (HTM) (PPT)